Mirae Asset Global Etfs Holdings Ltd. Arcutis Biotherapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 50,444 shares of ARQT stock, worth $524,617. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,444Holding current value
$524,617% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
193Shares Held
127MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.6MShares$120 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$104 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$102 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$91.4 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$89.7 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $626M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...